Loading...
XHKG8307
Market cap9mUSD
Nov 11, Last price  
0.19HKD
Name

Medicskin Holdings Ltd

Chart & Performance

D1W1MN
XHKG:8307 chart
P/E
—
P/S
1.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-3.87%
Rev. gr., 5y
-0.92%
Revenues
49m
+7.89%
51,607,00065,041,00066,738,00060,073,00062,062,00057,793,00051,449,00048,046,00041,713,00049,147,00045,541,00049,135,000
Net income
-3m
L+2.42%
14,532,00013,737,0003,328,0002,354,0003,168,0002,533,000-5,480,000-3,237,000953,0003,922,000-2,976,000-3,048,000
CFO
11m
+223.97%
20,532,00022,577,0006,418,0001,841,00016,331,0006,495,0004,212,00014,910,0009,147,0004,294,0003,246,00010,516,000
Dividend
Jul 05, 20210.025 HKD/sh

Profile

Medicskin Holdings Limited, an investment holding company, provides medical skin care services primarily in Hong Kong. It operates Medicskin centers, which provides various medical skin care services for the treatment of skin diseases and problems, such as acne, pigmentation, rosacea, dermatitis, eczema, and warts, as well as improvement of appearance through skin rejuvenation, facial sculpturing, and body contouring treatments; and treatment of acne scars and enlarged pores, removal of undesirable naevi, and hair removal. The company also offers derma fillers and facial contouring, intense focused ultrasound and ultrasound, radio frequency, lasers and light sources, laser and RF energy, and other treatments; skincare products; and health management services. In addition, it provides preventive health care services, such as genetic tests, history and physical examination, laboratory tests, diagnostics and imaging, and body check services; men's face, skin, and body care services; and shingles and human papillomavirus vaccines. The company was founded in 2000 and is headquartered in Central, Hong Kong. Medicskin Holdings Limited is a subsidiary of Topline Worldwide Limited.
URL
https://www.medicskinholdings.com/
IPO date
Dec 18, 2014
Employees
28
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
49,135
7.89%
45,541
-7.34%
49,147
17.82%
Cost of revenue
34,369
8,863
7,010
Unusual Expense (Income)
NOPBT
14,766
36,678
42,137
NOPBT Margin
30.05%
80.54%
85.74%
Operating Taxes
(22)
(2)
276
Tax Rate
0.66%
NOPAT
14,788
36,680
41,861
Net income
(3,048)
2.42%
(2,976)
-175.88%
3,922
311.54%
Dividends
(9,918)
Dividend yield
10.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
(14,165)
6,705
6,739
Long-term debt
5,757
17,149
30,593
Deferred revenue
Other long-term liabilities
739
700
700
Net debt
(15,335)
17,481
21,858
Cash flow
Cash from operating activities
10,516
3,246
4,294
CAPEX
(1,397)
(2,300)
(1,965)
Cash from investing activities
(1,397)
(5,675)
(1,820)
Cash from financing activities
(7,210)
(6,739)
(17,944)
FCF
11,830
53,506
29,166
Balance
Cash
6,927
6,373
15,474
Long term investments
Excess cash
4,470
4,096
13,017
Stockholders' equity
(2,131)
1,448
21,183
Invested Capital
16,208
22,339
20,246
ROIC
76.73%
172.27%
350.63%
ROCE
104.89%
154.19%
126.68%
EV
Common stock shares outstanding
396,736
396,736
396,736
Price
0.26
2.00%
0.25
 
Market cap
101,168
2.00%
99,184
 
EV
115,336
134,506
EBITDA
24,157
46,003
51,868
EV/EBITDA
2.51
2.59
Interest
509
779
396
Interest/NOPBT
3.45%
2.12%
0.94%